ISR IsoRay

Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020

Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020

Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT

RICHLAND, Wash., Nov. 02, 2020 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2021 ended September 30, 2020 on Tuesday, November 10, 2020, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2021 after the close of the U.S. stock markets on November 10, 2020.

To listen to the conference call, please dial (877) 407-8035. For callers outside the U.S., please dial (201) 689-8035.

The conference call will be simultaneously webcast and can be accessed at by clicking on the link. The webcast will be available until November 10, 2021 following the conference call.

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu (Cesium-131) brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting . Follow us on and . Join us on .

Contact
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747
EN
02/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IsoRay

 PRESS RELEASE

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in C...

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) --   ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluat...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief...

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscape SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company’s Chief Financial Officer, effective today....

 PRESS RELEASE

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Dire...

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company’s Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK’s U.S. Commercial business, a position she has held since September 2019. In ...

Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch